Amarin Corp Plc (AMRN)

[Whalatane]

CBB. The reason the stock shot up was because of this trial

https://www.healio.com/news/cardiology/20190518/orion3-inclisiran-safely-reduces-ldl-by-more-than-50?gclid=CjwKCAjwy7CKBhBMEiwA0Eb7aiUjgawDzOCFOeIfoLCQY2HeFfT6N3NJEzePllvS5U34-F0DOzP4NBoCR-EQAvD_BwE

Try and think of it this way

AMRN comes out with Vascepa 2.0 ...that you only needed to take once every Sunday night AND has very solid patent protection AND has same efficacy and safety as Vascepa 1.0
What would BP pay for that ?
Think of the business value here ....AMRN can charge the same for their once a week Vascepa 2.0 as the generics charge for the entire week for generic Vascepa 1.0
. They could probably even charge more because of the ease of use ...one night a week dosing vs twice a day dosing .
So if the generics are charging $50 WAC for 28 caps of V 1.0. ( 1 wk supply ) ...AMRN could charge the same or higher for their once a week Sunday night dose ALONE

By the way ...you have yet to tell me how much Inclisiran Novartis has sold in the US so far ....if you think NVS's Ceo made such a great deal

Kiwi